IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF

被引：0
|
作者：
Kao, Jia-Horng [1 ]
Chuang, Wan-Long [2 ]
Chen, Chi-Yi [3 ]
Ahn, Sang Hoon [4 ]
Fung, Scott K. [5 ]
Elkhashab, Magdy [6 ]
Hann, Hie-Won L. [7 ]
Ravendhran, Natarajan [8 ]
Nguyen, Tuan T. [9 ]
Tan, Susanna [10 ]
Flaherty, John F. [10 ]
Gagger, Anuj [10 ]
Gao, Bing [10 ]
Brainard, Diana M. [10 ]
Phan, Charles G. [11 ]
Lim, Young-Suk [12 ]
Ferret, Maria Asuncion Buti [13 ]
Lampertico, Pietro [14 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan
[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, Kaohsiung, Taiwan
[3] Chia Yi Christian Hosp, Dept Internal Med, Chiayi, Taiwan
[4] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea
[5] Univ Toronto, Toronto, ON, Canada
[6] Toronto Liver Ctr, Res, Toronto, ON, Canada
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[8] Digest Dis Associates PA, Wyomissing, PA USA
[9] T Nguyen Res & Educ Inc, San Diego, CA USA
[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[11] Mem Hermann Sugar Land, Sugar Land, TX USA
[12] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Liver Ctr, Seoul, South Korea
[13] Hosp Univ Vall dHebron, Dept Internal Med, Liver Unit, Barcelona, Spain
[14] Fdn Irccs Ca Granda Osped Maggiore Policlin, CRC AM & A Migliavacca Ctr Liver Dis, Div Gastroenterol & Hepatol, Milan, Italy
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
795
引用
收藏
页码：484A / 484A
页数：1
相关论文
共 50 条
  • [41] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
    Goorney, B.
    Perez, K.
    HIV MEDICINE, 2019, 20 : 39 - 39
  • [42] EFFECTIVENESS AND SAFETY OF SWITCHING TENOFOVIR DISOPROXIL FUMARATE AND ENTECAVIR TO TENOFOVIR ALAFENAMIDE FUMARATE ( TAF) IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B VIRUSINFECTED PATIENTS WITH ONEMINUTE OSTEOPOROSIS RISK TEST
    Li, Hui
    Li, Chunmei
    Wei, Jia
    Liu, Yunhua
    Gong, Ming
    Zhang, Ruyi
    Geng, Jiawei
    Wang, Hongyan
    Yu, Zhijian
    Wang, Zi
    Liu, Xiang
    HEPATOLOGY, 2023, 78 : S513 - S513
  • [43] Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
    Lim, Young-Suk
    Ide, Tatsuya
    Strasser, Simone I.
    Yoon, Ki Tae
    Paik, Seung Woon
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Subramanian, Mani
    Mangia, Alessandra
    Simon, Krzysztof
    Kwan, Peter
    Gane, Edward J.
    HEPATOLOGY, 2016, 64 : 940A - 940A
  • [44] Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
    Orkin, Chloe
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Van der Cam, Bernard
    De Wet, Joseph
    Rockstroh, Jurgen
    Lazzarin, Adriano
    Rijnders, Bart
    Podzamczer, Daniel
    Thalme, Anders
    Stoeckle, Marcel
    Porter, Danielle
    Liu, Hui
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [45] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [46] ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) RISK PROFILE OF TENOFOVIR ALAFENAMIDE (TAF) VERSUS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV (CHB) PATIENTS UNDER ANTIVIRAL THERAPY FOR 2 YEARS
    Fung, Scott K.
    Ahn, Sang Hoon
    Chen, Chi-Yi
    Elkhashab, Magdy
    Hann, Hie-Won L.
    Jablkowski, Maciej S.
    Kim, Yoon Jun
    Yurdaydin, Cihan
    Peng, Cheng-Yuan
    Tuan Nguyen
    Yatsuhashi, Hiroshi
    Inokuma, Tetsuro
    Tan, Susanna K.
    Flaherty, John F.
    Wang, Hongyuan
    Osinusi, Anu O.
    Temme, Lauren
    Lum, Ernie
    Lam, Kelly
    Abdurakhmanov, Dzhamal
    Lim, Young-Suk
    Buti, Maria
    HEPATOLOGY, 2021, 74 : 470A - 471A
  • [47] Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment
    Mills, Tony
    Andrade, Jamie
    Diperri, Giovanni
    Van Lunzen, Jan
    Koenig, Ellen
    Elion, Richard
    Cavassini, Matthias
    Madruga, Jose Valdez
    Brunetta, Jason
    Shamblaw, David
    Dejesus, Edwin
    Cohen, Calvin
    Plummer, Andrew
    Liu, Yapei
    McCallister, Scott
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [48] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    HIV MEDICINE, 2020, 21 : 12 - 12
  • [49] Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
    Kityo, C.
    Hagins, D.
    Koenig, E.
    Avihingsanon, A.
    Chetchotisakd, P.
    Supparatpinyo, K.
    Gankina, N.
    Pokrovsky, V.
    Voronin, E.
    Stephens, J. L.
    DeJesus, E.
    Wang, H.
    Acosta, R.
    Brainard, D.
    Martin, H.
    Makadzange, T. A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 4 - 4
  • [50] Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
    Orkin, C.
    DeJesus, E.
    Ramgopal, M.
    Crofoot, G.
    Ruane, P.
    LaMarca, A.
    Mills, A.
    Van der Cam, B.
    De Wet, J.
    Rockstroh, J.
    Lazzarin, A.
    Rijnders, B.
    Podzamczer, D.
    Thalme, A.
    Stoeckle, M.
    Chu, H.
    Porter, D.
    Liu, H.
    Cheng, A.
    Quirk, E.
    SenGupta, D.
    Cao, H.
    HIV MEDICINE, 2017, 18 : 21 - 21
12345